Ketamine One Capital Limited announced that the details of its common shares' listings on the OTC markets and the Frankfurt Stock Exchange has changed. The changes come after its spin-out transaction of Milgauss Investments Ltd, announced earlier this year.
The Vancouver, British Columbia-based company told its investors that as of October 15, 2021, Ketamine One’s common shares will be listed under a new CUSIP number (492556105) and ISIN number (CA4925561058).
On the Frankfurt Stock Exchange, the psychedelic company’s listing has its stock ticker symbol changed from ‘MYO’ to ‘6FC’, while the new WKN number is ‘A3C5JN’.
READ: Ketamine One is conducting its inaugural research studies with Biostrap across multiple locations
Ketamine One is also working with OTC markets and other applicable regulatory agencies to become ‘15c2-11 Certified’ under Rule 15c2-11 of the Securities and Exchange Commission of the United States.
The company said that the certification wouldn’t allow Ketamine One’s common shares to be eligible for proprietary broker-dealer quotations and would be labeled as ‘Unsolicited-Only’, making it difficult for investors to trade in the common shares through their brokerage firms.
Unsolicited-Only stocks are described by OTC markets as having a higher risk of wider spreads, increased volatility, and price dislocations. Besides, the psychedelic firm’s certified status under rule 15c2-11 will have a reasonable basis for believing that the information is accurate and from reliable sources.
Ketamine One’s shares were delisted from the NEO Exchange on Thursday, Oct. 14, 2021. Then, the new Ketamine One shares were listed for trading on the NEO Exchange the following day under the same ‘MEDI’ trading symbol. Subsequently, Milgauss is now a privately held reporting issuer following the closing of the transaction.
The mental health treatment-focused firm is working on consolidating medical clinics and positioning itself as a leader in the psychedelic mental health treatments in North America. Ketamine One is working to provide the critical infrastructure needed to develop and deliver breakthrough mental health treatments.
Contact Ritika at ritika@proactiveinvestors.com